tirzepatide or ozempic for weight loss In adults with obesity but not diabetes, leads to significantly greater than semaglutide over 72 weeks, and nearly double the patients on tirzepatide meet the 25% weight-loss target. http://ms.spr.ly/6183SkuIL Weight Loss Blog – Maryland

[PubMed: 10224068] 248

In addition to glycemic control and weight loss, certain GLP-1 receptor agonists have FDA-approved indications to lower the risk for major adverse cardiovascular events, address moderate to severe obstructive sleep apnea, and, most recently, reduce the risk for worsening kidney disease, kidney failure, and cardiovascular death

This is where hangover IV therapy has gained popularity as a direct approach to addressing the physiological impact of alcohol

Gastrointestinal Risks and Safety Concerns Available evidence indicates that retatrutide may cause several side effects, most commonly affecting the digestive system